Literature DB >> 29183270

Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.

Matthew R Beymer1,2, Ryan M Kofron3, Chi-Hong Tseng4, Robert K Bolan1, Risa P Flynn1, Jennifer M Sayles3, Mario J Perez5, Wilbert C Jordan6, Raphael J Landovitz2,3.   

Abstract

Post-exposure prophylaxis (PEP) is a promising but under-utilized strategy for HIV prevention in high-risk populations. Between March 2010 and June 2011, two community-based clinics in Los Angeles County provided PEP in a pilot program to 267 unique individuals. Courses were primarily dispensed to men who have sex with men (84%) and consisted overwhelmingly of a three-drug antiretroviral therapy regimen containing two nucleoside reverse transcriptase inhibitors and either an integrase inhibitor (raltegravir) or a boosted protease inhibitor (lopinavir/ritonavir). Approximately 64% of all PEP courses were followed for at least 12 weeks, and seven individuals seroconverted. Of the seven seroconversions, six had subsequent re-exposure. The low rate of PEP failure calls for expanded funding for PEP in other jurisdictions.

Entities:  

Keywords:  Antiretroviral therapy; HIV; North America; high-risk behavior; homosexual

Mesh:

Substances:

Year:  2017        PMID: 29183270      PMCID: PMC5843554          DOI: 10.1177/0956462417743158

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  13 in total

1.  HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.

Authors:  Allan E Rodríguez; Amanda D Castel; Carrigan L Parish; Sarah Willis; Daniel J Feaster; Michael Kharfen; Gabriel A Cardenas; Kira Villamizar; Michael Kolber; Liliana Vázquez-Rivera; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

2.  HIV-Negative Partnered Men's Willingness to Use Non-Occupational Post-Exposure Prophylaxis and Associated Factors in a U.S. Sample of HIV-Negative and HIV-Discordant Male Couples.

Authors:  Jason W Mitchell; Amber I Sophus; Andrew E Petroll
Journal:  LGBT Health       Date:  2015-11-13       Impact factor: 4.151

3.  Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California.

Authors:  Matthew R Beymer; Robert E Weiss; Robert K Bolan; Ryan M Kofron; Risa P Flynn; David L Pieribone; Sonali P Kulkarni; Raphael J Landovitz
Journal:  Open Forum Infect Dis       Date:  2017-04-04       Impact factor: 3.835

4.  Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.

Authors:  Shambavi Subbarao; Ronald A Otten; Artur Ramos; Caryn Kim; Eddie Jackson; Michael Monsour; Debra R Adams; Sheila Bashirian; Jeffrey Johnson; Vincent Soriano; Ana Rendon; Michael G Hudgens; Salvatore Butera; Robert Janssen; Lynn Paxton; Alan E Greenberg; Thomas M Folks
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

5.  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.

Authors:  Adelisa L Panlilio; Denise M Cardo; Lisa A Grohskopf; Walid Heneine; Clara Sue Ross
Journal:  MMWR Recomm Rep       Date:  2005-09-30

6.  Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

Authors:  R A Otten; D K Smith; D R Adams; J K Pullium; E Jackson; C N Kim; H Jaffe; R Janssen; S Butera; T M Folks
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

8.  Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-05-06       Impact factor: 17.586

Review 9.  Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-09-25

Review 10.  Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies.

Authors:  Cadi Irvine; Kieren J Egan; Zara Shubber; Koen K A Van Rompay; Rachel L Beanland; Nathan Ford
Journal:  Clin Infect Dis       Date:  2015-06-01       Impact factor: 9.079

View more
  1 in total

1.  Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients.

Authors:  Maria Bañó; Constanza Morén; Sergio Barroso; Diana Luz Juárez; Mariona Guitart-Mampel; Ingrid González-Casacuberta; Judith Canto-Santos; Ester Lozano; Agathe León; Enric Pedrol; Òscar Miró; Ester Tobías; Josep Mallolas; Jhon F Rojas; Francesc Cardellach; Esteban Martínez; Gloria Garrabou
Journal:  Front Genet       Date:  2020-05-26       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.